Cysteinyl leukotrienes and their receptors: molecular and functional characteristics - PubMed (original) (raw)
Review
doi: 10.1159/000312669. Epub 2010 Jun 2.
Affiliations
- PMID: 20516735
- DOI: 10.1159/000312669
Free article
Review
Cysteinyl leukotrienes and their receptors: molecular and functional characteristics
R K Singh et al. Pharmacology. 2010.
Free article
Abstract
The cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory lipid mediators synthesized from arachidonic acid by a variety of cells including mast cells, eosinophils, basophils and macrophages. The family includes leukotriene C(4) (LTC(4)), leukotriene D(4) (LTD(4)) and leukotriene E(4) (LTE(4)), which are potent biological mediators in the pathophysiology of inflammatory diseases and trigger contractile and inflammatory processes through the specific interaction with cell surface receptors, belonging to the superfamily of G-protein-coupled receptor. Pharmacological characterizations have suggested the existence of at least 2 types of CysLT receptors based on potency of agonist and antagonist, designated as CysLT(1) and CysLT(2). The CysLT(1) receptors are mostly expressed in lung smooth muscle cells, interstitial lung macrophages and the spleen, and it has been studied a lot elucidating its role in the etiology of airway inflammation and asthma. On the other hand, CysLT(2) receptors are present in the heart, brain and adrenal glands. This review discusses the role of CysLTs and their receptor in the pathophysiology of various inflammatory disorders. The understanding of CysLTs and their receptors in allergic airway disease is currently limited to CysLT(1)-receptor-mediated effects, and the role of the CysLT(2) receptors is pharmacologically less well defined, as there is no specific antagonist available yet. Specific CysLT(2)-receptor-selective antagonists would be very helpful to identify the precise role of CysLT and their receptors. Some recent evidence indicates the existence of additional receptor subtypes and requires further investigation for a better understanding of the role of the CysLT receptors. This review is an effort to summarize the localization, regulation and expression pattern along with the molecular and functional pharmacology of the CysLT receptors and to discuss their role in the pathophysiology of different diseases along with the recent update.
Similar articles
- International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions.
Bäck M, Dahlén SE, Drazen JM, Evans JF, Serhan CN, Shimizu T, Yokomizo T, Rovati GE. Bäck M, et al. Pharmacol Rev. 2011 Sep;63(3):539-84. doi: 10.1124/pr.110.004184. Pharmacol Rev. 2011. PMID: 21771892 Review. - Molecular and functional aspects of human cysteinyl leukotriene receptors.
Capra V. Capra V. Pharmacol Res. 2004 Jul;50(1):1-11. doi: 10.1016/j.phrs.2003.12.012. Pharmacol Res. 2004. PMID: 15082024 Review. - The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor.
Takasaki J, Kamohara M, Matsumoto M, Saito T, Sugimoto T, Ohishi T, Ishii H, Ota T, Nishikawa T, Kawai Y, Masuho Y, Isogai T, Suzuki Y, Sugano S, Furuichi K. Takasaki J, et al. Biochem Biophys Res Commun. 2000 Aug 2;274(2):316-22. doi: 10.1006/bbrc.2000.3140. Biochem Biophys Res Commun. 2000. PMID: 10913337 - Differential signaling of cysteinyl leukotrienes and a novel cysteinyl leukotriene receptor 2 (CysLT₂) agonist, N-methyl-leukotriene C₄, in calcium reporter and β arrestin assays.
Yan D, Stocco R, Sawyer N, Nesheim ME, Abramovitz M, Funk CD. Yan D, et al. Mol Pharmacol. 2011 Feb;79(2):270-8. doi: 10.1124/mol.110.069054. Epub 2010 Nov 15. Mol Pharmacol. 2011. PMID: 21078884 - The role of leukotrienes in the pathophysiology of inflammatory disorders: is there a case for revisiting leukotrienes as therapeutic targets?
Sharma JN, Mohammed LA. Sharma JN, et al. Inflammopharmacology. 2006 Mar;14(1-2):10-6. doi: 10.1007/s10787-006-1496-6. Inflammopharmacology. 2006. PMID: 16835707 Review.
Cited by
- Exacerbation of atherosclerosis, hyperlipidemia and inflammation by MK886, an inhibitor of leukotriene biosynthesis, in obese and diabetic mice.
Keever K, Askari B. Keever K, et al. Curr Res Pharmacol Drug Discov. 2024 Oct 10;7:100203. doi: 10.1016/j.crphar.2024.100203. eCollection 2024. Curr Res Pharmacol Drug Discov. 2024. PMID: 39497763 Free PMC article. - Drug fever-an immune-mediated delayed type hypersensitivity reaction to Vinca alkaloids in pediatric oncology patients, possibly mediated by cysteinyl leukotrienes.
Kidon MI, Haj Yahia S, Abebe-Campino G, Agmon-Levin N, Yelon M. Kidon MI, et al. Front Allergy. 2024 Aug 6;5:1361403. doi: 10.3389/falgy.2024.1361403. eCollection 2024. Front Allergy. 2024. PMID: 39166180 Free PMC article. - The Role of Exhaled Breath Condensate in Chronic Inflammatory and Neoplastic Diseases of the Respiratory Tract.
Kita K, Gawinowska M, Chełmińska M, Niedoszytko M. Kita K, et al. Int J Mol Sci. 2024 Jul 5;25(13):7395. doi: 10.3390/ijms25137395. Int J Mol Sci. 2024. PMID: 39000502 Free PMC article. Review. - Montelukast Influence on Lung in Experimental Diabetes.
Gales C, Stoica B, Rusu-Zota G, Nechifor M. Gales C, et al. Medicina (Kaunas). 2024 Apr 30;60(5):749. doi: 10.3390/medicina60050749. Medicina (Kaunas). 2024. PMID: 38792932 Free PMC article. - 1,4-dihydroxy quininib activates ferroptosis pathways in metastatic uveal melanoma and reveals a novel prognostic biomarker signature.
Tonelotto V, Costa-Garcia M, O'Reilly E, Smith KF, Slater K, Dillon ET, Pendino M, Higgins C, Sist P, Bosch R, Passamonti S, Piulats JM, Villanueva A, Tramer F, Vanella L, Carey M, Kennedy BN. Tonelotto V, et al. Cell Death Discov. 2024 Feb 10;10(1):70. doi: 10.1038/s41420-023-01773-8. Cell Death Discov. 2024. PMID: 38341410 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous